Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Oncogene

• Publication date

  2007-10-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1210503PMID 17486068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Clathrin-independent endocytosis of ubiquitinated cargos.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005influential reference
• Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

  2005cited by this paper
• ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004influential reference
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

  2004cited by this paper
• Faculty Opinions recommendation of Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Negative receptor signalling.

  2003cited by this paper
• A mutant EGF‐receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling

  2002cited by this paper
• A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• The ErbB receptor tyrosine family as signal integrators.

  2001cited by this paper
• Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer

  2001cited by this paper
• Regulation of Receptor Tyrosine Kinase Signaling by Endocytic Trafficking

  2001cited by this paper
• The C‐terminus of the kinase‐defective neuregulin receptor ErbB‐3 confers mitogenic superiority and dictates endocytic routing

  1999cited by this paper
• Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers

  1999influential reference
• ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors*

  1999cited by this paper
• Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.

  1999cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.

  1996cited by this paper
• All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*)

  1996cited by this paper
• ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

  1996cited by this paper
• Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

  1994cited by this paper
• Ligand-induced transformation by a noninternalizing epidermal growth factor receptor.

  1990cited by this paper
• Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

  1989cited by this paper

• A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)

  2026cites this paper
• A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer

  2025cites this paper
• Epsin3 promotes non-small cell lung cancer progression via modulating EGFR stability

  2025cites this paper
• E3 ubiquitin-protein ligase CBL inhibits non-small cell lung cancer progression via ubiquitination and degradation of KDR

  2025cites this paper
• Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells

  2025cites this paper
• Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.

  2025cites this paper
• The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.

  2024cites this paper
• Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

  2024cites this paper
• Effects and Mechanisms of Luteolin, a Plant-Based Flavonoid, in the Prevention of Cancers via Modulation of Inflammation and Cell Signaling Molecules

  2024cites this paper
• Insights into the role of derailed endocytic trafficking pathway in cancer: From the perspective of cancer hallmarks.

  2024cites this paper
• EGFR mutations and abnormal trafficking in cancers

  2024cites this paper
• Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to target squamous cell cancers with tyrosine kinase inhibitors.

  2024cites this paper
• Effect of Interval Between Neoadjuvant Chemotherapy and Surgery on Oncological Outcomes in Poor Responders With Locally Advanced Breast Cancer

  2024cites this paper
• The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies

  2024cites this paper
• Knockout of c-Cbl/Cbl-b slows c-Met trafficking resulting in enhanced signaling in corneal epithelial cells

  2023cites this paper
• Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor

  2023cites this paper
• Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators

  2023cites this paper
• Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer

  2023cites this paper
• Cellular Factors Involved in the Hepatitis D Virus Life Cycle

  2023cites this paper
• Kremen2 drives the progression of non-small cell lung cancer by preventing SOCS3-mediated degradation of EGFR

  2023cites this paper
• Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

  2022cites this paper
• Tuning of cytokine signaling through imbalanced abundances of receptors and kinases

  2022cites this paper
• Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies

  2022cites this paper
• Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

  2021cites this paper
• Therapeutic anti-PD-L1 antibody affects ESCRT-mediated functions in cells expressing oncogenic EGFR

  2021cites this paper
• EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance

  2021cites this paper
• Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches

  2021cites this paper
• Proteomic investigation of Cbl and Cbl-b in neuroblastoma cell differentiation highlights roles for SHP-2 and CDK16

  2021cites this paper
• Chemical genetics screen identifies COPB2 tool compounds that alters ER stress response and induces RTK dysregulation in lung cancer cells.

  2021cites this paper
• DRAM1 plays a tumor suppressor role in NSCLC cells by promoting lysosomal degradation of EGFR

  2020cites this paper
• The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer

  2020cites this paper
• To be more precise: the role of intracellular trafficking in development and pattern formation

  2020cites this paper
• PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.

  2020cites this paper
• The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer

  2020cites this paper
• Coiled coil control of growth factor and inhibitor-dependent EGFR trafficking and degradation

  2020cites this paper
• The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview

  2020cites this paper
• EGFRvIII: An Oncogene with Ambiguous Role

  2019cites this paper
• Irreversible modifications of receptor tyrosine kinases

  2018cites this paper
• Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines.

  2018cites this paper
• Trafficking of Adhesion and Growth Factor Receptors and Their Effector Kinases.

  2018cites this paper
• Role for ERK1/2-dependent activation of FCHSD2 in cancer cell-selective regulation of clathrin-mediated endocytosis

  2018cites this paper
• Regulation of EGFR Endocytosis by CBL During Mitosis

  2018cites this paper
• Exploring integrin and growth factor receptor crosstalk mechanisms

  2018cites this paper
• EGFR Trafficking in Physiology and Cancer.

  2018cites this paper
• ARF promotes the degradation of the Epidermal Growth Factor Receptor by the lysosome

  2018cites this paper
• The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms

  2018cites this paper
• Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.

  2018cites this paper
• ERK1/2-dependent activation of FCHSD2 drives cancer cell-selective regulation of clathrin-mediated endocytosis

  2018cites this paper
• University of Southern Denmark Cylindromatosis Tumor Suppressor Protein ( CYLD ) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor

  2017cites this paper
• Oncogenic role of rab escort protein 1 through EGFR and STAT3 pathway

  2017cites this paper
• Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL

  2017cites this paper
• CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.

  2017cites this paper
• The Role of Ubiquitination and Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate in the Degradation of the Adrenomedullin Type I Receptor

  2017cites this paper
• Crosstalk between CLCb/Dyn1-Mediated Adaptive Clathrin-Mediated Endocytosis and Epidermal Growth Factor Receptor Signaling Increases Metastasis.

  2017cites this paper
• The E3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells.

  2017cites this paper
• Spiroplasma eriocheiris Adhesin-Like Protein (ALP) Interacts with Epidermal Growth Factor (EGF) Domain Proteins to Facilitate Infection

  2017cites this paper
• Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

  2017influential citation
• Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor*

  2017cites this paper
• University of Southern Denmark Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor Sanchez-Quiles,

  2017cites this paper
• Emerging functions of the EGFR in cancer

  2017cites this paper
• CYLD deubiquitinase is necessary for proper ubiquitination and degradation of the epidermal growth factor receptor

  2017cites this paper
• The E 3 ubiquitin ligase Cbl-b inhibits tumor growth in multidrug-resistant gastric and breast cancer cells

  2017cites this paper
• CHARACTERIZATION OF THE UBIQUITIN LIGASE, UBE4B, IN ENDOCYTIC TRAFFICKING

  2017cites this paper
• Lung Injury and Lung Cancer

  2017cites this paper
• Quantitative microscopy workflows for the study of cellular receptor trafficking

  2017cites this paper
• Syddansk Universitet Cylindromatosis Tumor Suppressor Protein ( CYLD ) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor

  2017cites this paper
• Mechanisms of resistance to EGFR-targeted drugs: lung cancer

  2016cites this paper
• Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki)

  2016cites this paper
• Chapter Six - The Ubiquitin Network in the Control of EGFR Endocytosis and Signaling.

  2016cites this paper
• Network Architecture Predisposes an Enzyme to Either Pharmacologic or Genetic Targeting.

  2016cites this paper
• AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

  2016cites this paper
• Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation

  2016cites this paper
• Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6*

  2016cites this paper
• Stress-induced endocytosis and degradation of epidermal growth factor receptor are two independent processes

  2016cites this paper
• Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

  2015cites this paper
• EGF-dependent re-routing of vesicular recycling switches spontaneous phosphorylation suppression to EGFR signaling

  2015cites this paper
• Cell Regulation by Phosphotyrosine-Targeted Ubiquitin Ligases

  2015cites this paper
• EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.

  2015cites this paper
• Carcinoma cells induce lumen filling and EMT in epithelial cells through soluble E-cadherin-mediated activation of EGFR

  2015cites this paper
• Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells

  2015cites this paper
• αPIX Is a Trafficking Regulator that Balances Recycling and Degradation of the Epidermal Growth Factor Receptor

  2015cites this paper
• Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

  2015cites this paper
• Altered trafficking of mutated growth factor receptors and their associated molecules

  2014influential citation
• Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.

  2014cites this paper
• EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy

  2014cites this paper
• KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport.

  2014cites this paper
• An In Vivo EGF Receptor Localization Screen in C. elegans Identifies the Ezrin Homolog ERM-1 as a Temporal Regulator of Signaling

  2014cites this paper
• EGF receptor trafficking: consequences for signaling and cancer

  2014cites this paper
• Lung Injury and Lung Cancer Caused by Cigarette Smoke-Induced Oxidative Stress: Molecular Mechanisms and Therapeutic Opportunities Involving the Ceramide-Generating Machinery and Epidermal Growth Factor Receptor

  2014cites this paper
• Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

  2014cites this paper
• Ubiquitin–Proteasome System in the Hallmarks of Cancer

  2014cites this paper
• AKT Facilitates EGFR Trafficking and Degradation by Phosphorylating and Activating PIKfyve

  2013cites this paper
• ErbB receptors and their growth factor ligands in pediatric intestinal inflammation

  2013cites this paper
• THERAPEUTIC POTENTIAL OF EGFR DERIVED PEPTIDES IN BREAST CANCER

  2013cites this paper
• Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

  2013cites this paper
• Stress-Driven Endocytosis of Tyrosine-Phosphorylated EGFR Leads to Tumorigenesis: The Critical Role of Oxidative Stress

  2013cites this paper
• Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells

  2013cites this paper
• This information is current as EGFR Kinase Mutations Are Not Affected by Lung Cancer-Associated Growth Factor Receptor (EGFR) Antibodies Tumor Cell Killing Mechanisms of Epidermal

  2013cites this paper
• Endocytosis and cancer.

  2013cites this paper
• Regulation of Epidermal Growth Factor Receptor Signaling by Endocytosis in Normal and Malignant Cells

  2013cites this paper